Skip To Main Content
Patrick Wingrove on Muck Rack

Patrick Wingrove

Verified
London, New York
As seen in: Thomson Reuters, G1 Globo, MSN, MSN Australia, MSN Canada, MSN Ireland, MSN Malaysia, MSN Money Canada, MSN Singapore, MSN UK, MSN Venezuela and
Journalist @Reuters. History lover and jogger.

Get in touch with Patrick

Contact Patrick, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

CEO da Novo Nordisk diz que pílulas podem capturar 50% do mercado de produtos para emagrecimento até 2030

|
By Patrick Wingrove Verified
| Diário do Comércio (Belo Horizonte) Verified
As pílulas para emagrecer podem conquistar até metade do mercado global de medicamentos para obesidade até 2030, disse à Reuters nesta terça-feira (22) o diretor executivo da Novo Nordisk, enquanto a farmacêutica dinamarquesa se posiciona para uma mudança das injeções semanais. O presidente-executivo Mike Doustdar afirmou que a Novo Nordisk está se preparando para um mercado em que os comprimidos desempenham um papel muito maior.
Open in Who Shared Issue with article?

Novo Nordisk and UNICEF renew push to prevent childhood obesity

|
By Patrick Wingrove Verified, Vera Dvorakova, Milla Nissi-Prussak
| Think Pink (Podcast)
The expansion follows UNICEF’s 2025 Child Nutrition Report that found childhood obesity had overtaken underweight for the first time on record The logo of pharmaceutical company Novo is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, September 21, 2026. REUTERS/Tom Little International News via Reuters: Novo Nordisk and UNICEF have expanded their partnership to help prevent childhood overweight and obesity, the Danish drugmaker said on Tuesday.
Open in Who Shared View Duplicates (93) Issue with article?

Novo CEO says pills could capture 50% of weight-loss market by 2030

|
By Patrick Wingrove Verified
| MSN Verified
By Patrick Wingrove LONDON, Sept 22 - Weight-loss pills could capture as much as half of the global obesity drug market by 2030, Novo Nordisk's chief executive told Reuters on Tuesday, as the Danish drugmaker positions itself for a shift away from weekly injections. CEO Mike Doustdar said Novo was preparing for a market in which pills play a much larger role. The company has five oral treatments in development after beating rival Eli Lilly to market with the first obesity pill earlier this year.
Open in Who Shared View Duplicates (98) Issue with article?
See all 12,559 licensed articles (13,187 Total)